{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:59:48Z","timestamp":1777895988637,"version":"3.51.4"},"reference-count":17,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015725","name":"Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy","doi-asserted-by":"publisher","award":["1U01 CA180964"],"award-info":[{"award-number":["1U01 CA180964"]}],"id":[{"id":"10.13039\/100015725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR000371"],"award-info":[{"award-number":["UL1 TR000371"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA242845"],"award-info":[{"award-number":["R01CA242845"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA273168"],"award-info":[{"award-number":["R01CA273168"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012684","name":"Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston","doi-asserted-by":"publisher","award":["UL1 TR000371"],"award-info":[{"award-number":["UL1 TR000371"]}],"id":[{"id":"10.13039\/100012684","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP RP150535"],"award-info":[{"award-number":["RP RP150535"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP1100584"],"award-info":[{"award-number":["RP1100584"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.esmoop.2023.101609","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T15:30:38Z","timestamp":1698075038000},"page":"101609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study"],"prefix":"10.1016","volume":"8","author":[{"given":"S.","family":"Phadnis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.C.","family":"Daw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.E.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.M.","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Zaky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Gouda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.C.","family":"Morani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Amini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.J.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.A.","family":"Piha-Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Gorlick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.L.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2023.101609_bib1","first-page":"715","article-title":"Differential anti-vascular effects of mTOR or VEGFR pathway inhibition: a rational basis for combining RAD001 and PTK787\/ZK222584","volume":"65","author":"O\u2019Reilly","year":"2005","journal-title":"Proc Amer Assoc Cancer Res"},{"key":"10.1016\/j.esmoop.2023.101609_bib2","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.cllc.2012.12.001","article-title":"Preclinical rationale for PI3K\/Akt\/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer","volume":"14","author":"Gadgeel","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.esmoop.2023.101609_bib3","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2007.11.4017","article-title":"Phase I study of everolimus in pediatric patients with refractory solid tumors","volume":"25","author":"Fouladi","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.101609_bib4","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1158\/1078-0432.CCR-13-0071","article-title":"Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma","volume":"19","author":"Fox","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2023.101609_bib5","series-title":"CAPRELSA\u00ae (vandetanib) tablets, for oral use [package insert]","year":"2022"},{"key":"10.1016\/j.esmoop.2023.101609_bib6","series-title":"AFINITOR\u00ae (everolimus) tablets, for oral use [package insert]","year":"2022"},{"key":"10.1016\/j.esmoop.2023.101609_bib7","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1200\/JCO.2014.58.2635","article-title":"American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment","volume":"33","author":"Weber","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.101609_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100079","article-title":"Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study","volume":"6","author":"Cascone","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2023.101609_bib9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2023.101609_bib10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2023.101609_bib11","doi-asserted-by":"crossref","first-page":"7426","DOI":"10.1158\/1078-0432.CCR-17-1856","article-title":"In-depth genetic analysis of sclerosing epithelioid fibrosarcoma reveals recurrent genomic alterations and potential treatment targets","volume":"23","author":"Arbajian","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2023.101609_bib12","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1158\/1078-0432.CCR-13-2090","article-title":"High-resolution array CGH and gene expression profiling of alveolar soft part sarcoma","volume":"20","author":"Selvarajah","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2023.101609_bib13","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.1158\/1078-0432.CCR-11-0379","article-title":"Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer","volume":"17","author":"Glubb","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2023.101609_bib14","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1158\/1078-0432.CCR-15-1811","article-title":"Identification of a novel pathogenic germline KDR variant in melanoma","volume":"22","author":"Silva","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2023.101609_bib15","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s11060-016-2066-4","article-title":"Genetic risk variants in the CDKN2A\/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma","volume":"127","author":"Ghasimi","year":"2016","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.esmoop.2023.101609_bib16","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1158\/0008-5472.CAN-06-2855","article-title":"TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition","volume":"67","author":"Tsuda","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2023.101609_bib17","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/428789","article-title":"Alveolar soft part sarcomas: molecular pathogenesis and implications for novel targeted therapies","volume":"2012","author":"Mitton","year":"2012","journal-title":"Sarcoma"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292300844X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292300844X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:11:25Z","timestamp":1777623085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292300844X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S205970292300844X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101609","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101609","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101609"}}